Get notified when PBLS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Sole Source Supplier (new) — PBLS depends on sole source supplier Alcami for drug product manufacturing, creating supply chain risk.
- Biosecure Act (new) — U.S. legislation could restrict PBLS's use of Chinese CDMO WuXi, impacting manufacturing.
- Injection Site Reactions (new) — PBLS paused dosing in a healthy volunteer trial due to Grade 1-2 injection site reactions with the injectable formulation.
- Artbio Collaboration Termination (new) — ARTBIO notified PBLS of intent to opt out of all research programs, potentially reducing future collaboration funding.
PBLS files S-1/A to raise $600M in IPO at $18/share, with $75M Regeneron private placement
Filed June 9, 2026 · ~2 min read
Key Changes
-
high
PBLS plans to offer 33,333,334 shares at $18.00 per share, with expected proceeds of $600.0M gross for the company; net proceeds estimated at $553.1M.
The Offering verify on EDGAR → -
high
Regeneron will invest $75.0M in a concurrent private placement at 90% of the IPO price, contingent on the offering closing.
The Offering verify on EDGAR → -
high
Net proceeds of $553.1M plus $75.0M private placement and $50.0M Regeneron upfront payment expected to fund operations into 2H 2029.
Use of Proceeds verify on EDGAR →
4 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (PURR 10-K) is open in full — no account needed.
Partner
Trade PBLS commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 30, 2026 · How we verify